Your session is about to expire
← Back to Search
Lymph Node Mapping with Tc-99m Tilmanocept for Brain Cancer
Study Summary
This trial is testing whether a brain tumor's lymph nodes can be found by injecting a radioactive substance & scanning the body.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are allergic to dextran or similar substances.You had surgery to remove lymph nodes from your head or neck in the past.You are being considered for surgery to remove or take a sample of a suspected brain tumor, whether it's benign or malignant.You are able to receive a specific injection and imaging after surgery as determined by the study doctor or your treating neurosurgeon.
- Group 1: Cohort 2C: Tc-99m tilmanocept temporal lobe injection site
- Group 2: Cohort 2B: Tc-99m tilmanocept parietal lobe injection site
- Group 3: Cohort 2D: Tc-99m tilmanocept occipital lobe injection site
- Group 4: Cohort 1: Tc-99m tilmanocept
- Group 5: Cohort 3: Tc-99m tilmanocept stereotactic needle biopsy of tumor
- Group 6: Cohort 2A: Tc-99m tilmanocept frontal lobe injection site
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there availability for participants to join this clinical experiment?
"Affirmative. According to clinicaltrials.gov, this research endeavour is currently looking for qualified patients; it was initially published on December 3rd 2019 and edited most recently on January 28th 2022. The study necessitates 30 participants at a single medical facility."
What diseases are most commonly treated using Tc-99m tilmanocept?
"Tc-99m tilmanocept is most commonly deployed in the treatment of malignant melanoma. However, it has also proven useful for breast cancer diagnosis, oral carcinomas, and other medical imaging purposes."
What potential risks should individuals be aware of before taking Tc-99m tilmanocept?
"Considering the preliminary nature of this Phase 1 trial, our team at Power assigned Tc-99m tilmanocept a safety rating of 1 due to limited data regarding its efficacy and safety."
Could you elaborate on the other experiments that have been conducted involving Tc-99m tilmanocept?
"At present, 2 studies are underway researching the efficacy of Tc-99m tilmanocept with none having reached Phase 3. Available trials span 7 locations across London and California."
How many participants are being monitored in this clinical trial?
"Affirmative. Recent updates on clinicaltrials.gov demonstrate that this trial commenced its recruitment phase on December 3rd 2019 and is still actively searching for 30 participants at one location."
Share this study with friends
Copy Link
Messenger